Abstract Changes in antineoplastic treatments and transplant practices are driving shifts in
the epidemiology of invasive fungal diseases (IFDs). Patients with acute myelogenous …

Objective: Patients with hematologic malignancies are at substantial risk of developing
invasive fungal infections (IFI) that are associated with substantial morbidity and mortality …

Invasive fungal infections (IFIs) pose the most serious infectious risk to patients with
hematologic malignancies and in those undergoing hematopoietic stem cell transplantation …

Invasive fungal disease (IFD), predominantly aspergillosis, is associated with significant
morbidity and mortality in immunocompromised patients, especially those with …

Patients with hematologic malignancy and hematopoietic cell transplant (HCT) recipients
are at increased risk for invasive fungal infection (IFI) as a result of immunosuppression or …

Invasive fungal infection (IFI) is a persistent problem among critically ill and
immunocompromised patients, especially hematopoietic stem cell transplant or solid organ …

Invasive fungal infections contribute to the morbidity and mortality of immunosuppressed
patients treated for hematologic malignancy and those undergoing hematopoietic cell …

Fungal infections in oncology patients: update on epidemiolo... : Current Opinion in Oncology
Fungal infections in oncology patients: update on epidemiology, prevention, and treatment …

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in
immunocompromised patients. Patients with hematological malignancies undergoing …

Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma,
are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is …